Another phase II, randomized, open-label, multicentric clinical trial wants to evaluate HER2-related benefits of metformin as neoadjuvant chemotherapy with chemotherapy and trastuzumab in women diagnosed with HER2-positive primary breast cancer with the assessment of its effect on a 3-year disease free survival [69]. This evidence concerns the gene ERBB2 and breast carcinoma.